Melatonin Slows Skin Cell Aging by Quieting CXCL9 Inflammation

Melatonin suppresses inflammatory CXCL9 signaling and mitochondrial stress to slow senescence in dermal fibroblasts, according to a study published online October 19, 2026, in the Journal of Investigative Dermatology.

The paper comes from Kento Takaya, Mayuko Okura, and Russel J. Reiter, a group whose senior author has spent decades characterizing melatonin's biology beyond its best-known role in sleep regulation. Their target here is specific: the senescent dermal fibroblast, a cell that stops dividing but refuses to die quietly.

That refusal matters for skin. Senescent fibroblasts accumulate with age and secrete inflammatory signals. Those signals, collectively the senescence-associated secretory phenotype, are increasingly linked to chronic skin inflammation, impaired wound repair, and visible structural decline in the dermis.

What did the researchers actually block?

The study centers on two linked mechanisms. First, melatonin reduced signaling through CXCL9, a chemokine the authors tie to inflammatory crosstalk in aging skin. Second, it eased mitochondrial stress in the fibroblasts themselves.

That pairing is the story's core. Damaged mitochondria and inflammatory chemokine output typically reinforce each other in senescent cells. Break one arm of the loop, and the other weakens too. The authors report melatonin did both, with the result that fibroblasts showed fewer markers of senescence.

• Condition studied: dermal fibroblast senescence
• Key pathway suppressed: CXCL9-associated inflammatory signaling
• Second target: mitochondrial stress
• Published: October 19, 2026, Journal of Investigative Dermatology
• Authors: Kento Takaya, Mayuko Okura, Russel J. Reiter

Why should dermatologists care about a sleep hormone?

Melatonin is not a newcomer to skin biology. The molecule is synthesized in skin, and Reiter's earlier work established that it acts as a potent antioxidant in peripheral tissues. What's newer is framing it as a modulator of cellular senescence through a named chemokine axis.

CXCL9 is the detail worth flagging. Chemokines in this family recruit immune cells and amplify local inflammation. If senescent fibroblasts drive skin aging partly through CXCL9, the pathway becomes a druggable target, and melatonin a cheap, well-characterized candidate for modulating it.

In plain words: the study gives the field a specific molecular handle on how an old, cheap molecule might slow skin aging at the cellular source.

Where does this sit in the evidence hierarchy?

This is laboratory mechanistic work in human dermal fibroblasts, not a clinical trial. The findings do not establish efficacy in patients, and no dosing, formulation, or endpoint data in living skin appear in the publication record available at press time.

That limits what clinicians can do with it today. It doesn't change practice. It does change the research map, identifying CXCL9-associated inflammation and mitochondrial stress as joint targets whose suppression by melatonin reduced senescence markers in vitro.

The translational questions come fast from here: whether topical melatonin reaches dermal fibroblasts at active concentrations, whether the CXCL9 effect holds in photoaged skin in vivo, and whether senescence markers correlate with clinical outcomes dermatologists actually measure.

The next step, almost certainly already underway in follow-up work, is testing whether the melatonin-CXCL9 axis behaves the same way in intact human skin as it does in the culture dish.